Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.
You may also be interested in...
Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.
Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.
Vedolizumab, Empagliflozin And Vintafolide Receive Positive EU Opinions After CHMP Meeting
The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.